Cencora, Inc. (COR)

Cencora's stock has been influenced by several key events. The company reported strong Q2 fiscal 2025 earnings, surpassing analyst estimates and raising its full-year guidance. The acquisition of Retina Consultants of America (RCA) in January 2025 bolstered the U.S. Healthcare Solutions segment. Cencora exceeded third-quarter fiscal 2025 earnings and revenue estimates, but the stock experienced a dip due to broader market conditions. Several research firms raised their price targets for Cencora, contributing to a "Moderate Buy" consensus rating. Chairman Steven H. Collis sold 31,350 shares of company stock. Investor sentiment improved following an announcement by peer McKesson, which increased its long-term adjusted earnings growth target. Cencora's stock reached a new 52-week high of $310.58.

Cencora experiences some product-specific seasonality due to its "Seasonal Vaccines Program" for flu, COVID-19, and RSV vaccines. The company's international healthcare solutions segment has faced "demand softness in the clinical trial and outsourced pharma services markets." Cencora utilizes supply chain planning and real-time data to manage demand.

Cencora, Inc. is a global healthcare solutions company involved in pharmaceutical distribution and healthcare services. It operates through two segments: U.S. Healthcare Solutions and International Healthcare Solutions. Its major products and services include pharmaceutical distribution, global commercialization services, animal health products, consulting and technology solutions, and specialized offerings like biosimilar distribution and vaccine programs.

Cencora operates in over 50 countries across North America, the United Kingdom, Europe, and Asia Pacific. It has 26 pharmaceutical distribution centers in the U.S. and nine in Canada, along with packaging production facilities in both the U.S. and the UK.

Cencora's brand reputation has been shaped by its rebranding from AmerisourceBergen, lawsuits related to the American Opioid Epidemic, and operating under a corporate integrity agreement since 2018. In May 2024, Cencora disclosed a cyber incident that resulted in the exposure of patient information. Cencora promotes its commitment to ESG initiatives.

Cencora's ownership is predominantly institutional, with approximately 94.95% to 97.52% of the stock held by institutional shareholders. Major institutional owners include Vanguard Group Inc., Blackrock Inc., and State Street Corp. Walgreens Boots Alliance Inc. is the largest individual shareholder, although it has been systematically reducing its stake. Insiders hold between 6.78% and 13.97% of the company's stock, with some recent executive sales reported.